Skip to content
DataLookout
Menu

NCT06085755

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

StatusActive, Not Recruiting
PhasePhase 1/2
SponsorJeeyun Lee
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 6 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 2025 to Dec 1, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 65 words
    • Enrollment closed, study ongoing
    • Study completion pushed from Dec 2026 to Dec 1, 2028
    • Site details revised
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 2024 to Sep 30, 2024
    v5
  3. Notable Start date: Jun 2024 to Oct 2024v4
  4. Notable Start date: Dec 2023 to Jun 2024v3
  5. Notable Start date: Oct 2023 to Dec 2023
    • Primary completion date: Oct 2025 to Dec 2025
    • Study completion date: Oct 2026 to Dec 2026
    v2
  6. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Adverse events by NCI-CTCAE v5.0
Timeframe: through study completion, an average of 30 months
ORR (Objective response rate)
Timeframe: through study completion, an average of 30 months

Secondary (3)

Disease Control rate (CR+PR+SD)
Overall survival (OS)
Progression free survival (PFS)

Arms and interventions

Trastuzumab deruxtecan + AfatinibExperimental

The first part (PART A) will be in combination with T-DXd the starting dose of 20 mg afatinib MWF will be escalated to reach a maximum tolerated dose in patients with advanced gastric cancer patients with HER2-low, as defined by dose-limiting toxicity. The second part (PART B) will be expansion cohort, in which Afatinib will be taken in combination with T-DXd according to the recommended Phase 2 dose(RP2D) confirmed through Part A from cycle 1.

Drugs: Trastuzumab deruxtecan, Afatinib

Sites

1 site in 1 country

  • Samsung Medical CenterSeoul, South Korea